Drug Name: Orserdu

Indications: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

Active Ingredient: Elacestrant

Company: Stemline Therapeutics, Inc

Approval Date: 1/27/2023

More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *